References

Chaperone-mediated autophagy markers in Parkinson disease brains

10.1001/archneurol.2010.198 · ExternalCitation · doi-reference

Adenosine A2A receptor antagonist istradefylline (KW-6002) reduces “off” time in Parkinson’s disease: a double-blind, randomized, multicenter clinical trial (6002-US-005)

10.1002/ana.21315 · ExternalCitation · doi-reference

Lewy body extracts from Parkinson disease brains trigger α‐synuclein pathology and neurodegeneration in mice and monkeys

10.1002/ana.24066 · ExternalCitation · doi-reference

Gene delivery of neurturin to putamen and substantia nigra in P arkinson disease: a double‐blind, randomized, controlled trial

10.1002/ana.24436 · ExternalCitation · doi-reference

Magnetic resonance imaging–guided phase 1 trial of putaminal AADC gene therapy for Parkinson’s disease

10.1002/ana.25450 · ExternalCitation · doi-reference

Gene therapy with AAV 2‐ CDNF provides functional benefits in a rat model of P arkinson’s disease

10.1002/brb3.117 · ExternalCitation · doi-reference

Elie Chalhoub, The understanding of Parkinson’s disease through genetics and new therapies

10.1002/brb3.2577 · ExternalCitation · doi-reference

Gaucher disease: mutation and polymorphism spectrum in the glucocerebrosidase gene (GBA)

10.1002/humu.20676 · ExternalCitation · doi-reference

Randomized trial of modafinil for treating subjective daytime sleepiness in patients with Parkinson’s disease

10.1002/mds.10390 · ExternalCitation · doi-reference

Parkinson’s disease home diary: further validation amd implications for clinical trials

10.1002/mds.20248 · ExternalCitation · doi-reference

Movement disorder society-sponsored revision of the unified Parkinson’s disease rating scale (MDS-UPDRS): scale presentation and clinimetric testing results

10.1002/mds.22340 · ExternalCitation · doi-reference

Bioactivity of AAV2-neurturin gene therapy (CERE-120): differences between Parkinson’s disease and nonhuman primate brains

10.1002/mds.23442 · ExternalCitation · doi-reference

Trial of magnetic resonance–guided putaminal gene therapy for advanced Parkinson’s disease

10.1002/mds.27724 · ExternalCitation · doi-reference

Aromatic L-amino acid decarboxylase gene therapy enhances levodopa response in Parkinson’s Disease

10.1002/mds.27993 · ExternalCitation · doi-reference

Post-mortem studies of neurturin gene therapy for Parkinson’s disease: two subjects with 10 years CERE120 delivery

10.1002/mds.29518 · ExternalCitation · doi-reference

Persistent GDNF expression 45 Months after Putaminal Infusion of AAV2-GDNF in a patient with Parkinson’s disease

10.1002/mds.29820 · ExternalCitation · doi-reference

Intraputaminal delivery of adeno-associated virus serotype 2–glial cell line–derived neurotrophic factor in mild or moderate Parkinson’s disease

10.1002/mds.30193 · ExternalCitation · doi-reference

Loss of FBXO7 results in a Parkinson’s‐like dopaminergic degeneration via an RPL23–MDM2–TP53 pathway

10.1002/path.5312 · ExternalCitation · doi-reference

Characterization of behavioral and neurodegenerative changes following partial lesions of the nigrostriatal dopamine system induced by intrastriatal 6-hydroxydopamine in the rat

10.1006/exnr.1998.6848 · ExternalCitation · doi-reference

Modeling Parkinson’s disease in rats: an evaluation of 6-OHDA lesions of the nigrostriatal pathway

10.1006/exnr.2002.7891 · ExternalCitation · doi-reference

Viral vector-based models of Parkinson’s disease

10.1007/7854_2014_310 · ExternalCitation · doi-reference

Specific effects of platelet derived growth factor (PDGF) on fetal rat and human dopaminergic neurons in vitro

10.1007/bf00242187 · ExternalCitation · doi-reference

Neurorestorative effects of sub-chronic administration of ambroxol in rodent model of Parkinson’s disease

10.1007/s00210-019-01737-9 · ExternalCitation · doi-reference

Autophagy and UPS pathway contribute to nicotine-induced protection effect in Parkinson’s disease

10.1007/s00221-023-06765-9 · ExternalCitation · doi-reference

Molecular mechanisms of α-synuclein and GBA1 in Parkinson’s disease

10.1007/s00441-017-2704-y · ExternalCitation · doi-reference

Genetic risk factors in Parkinson’s disease

10.1007/s00441-018-2817-y · ExternalCitation · doi-reference

Catecholamines and Parkinson’s disease: tyrosine hydroxylase (TH) over tetrahydrobiopterin (BH4) and GTP cyclohydrolase I (GCH1) to cytokines, neuromelanin, and gene therapy: a historical overview

10.1007/s00702-023-02673-y · ExternalCitation · doi-reference

Initial treatment of Parkinson’s disease

10.1007/s11940-006-0013-y · ExternalCitation · doi-reference

Preparation and properties of a homogeneous aromatic l-amino acid decarboxylase from hog kidney

10.1016/0003-9861(70)90144-x · ExternalCitation · doi-reference

Hemiparkinsonism in monkeys after unilateral internal carotid artery artery infusion of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)

10.1016/0024-3205(86)90431-5 · ExternalCitation · doi-reference

IV. MPTP, MPP+ and mitochondrial function

10.1016/0024-3205(87)90299-2 · ExternalCitation · doi-reference

Protective effect of platelet-derived growth factor against 6-hydroxydopamine-induced lesion of rat dopaminergic neurons in culture

10.1016/0304-3940(96)12326-0 · ExternalCitation · doi-reference

Catechol-O-methyltransferase enzyme. Cofactor S-adenosyl-l-methionine and related mechanisms

10.1016/b978-0-12-381326-8.00004-1 · ExternalCitation · doi-reference

TheE3ubiquitin ligase SCF(Fbxo7) mediates proteasomal degradation of UXT isoform 2 (UXT-V2) to inhibit the NF-κB signaling pathway

10.1016/j.bbagen.2020.129754 · ExternalCitation · doi-reference

Platelet-derived growth factor signalling in neurovascular function and disease

10.1016/j.biocel.2022.106187 · ExternalCitation · doi-reference

Complex I deficiency in Parkinson’s disease frontal cortex

10.1016/j.brainres.2007.10.061 · ExternalCitation · doi-reference

An alpha-synuclein AAV gene silencing vector ameliorates a behavioral deficit in a rat model of Parkinson’s disease, but displays toxicity in dopamine neurons

10.1016/j.brainres.2011.04.036 · ExternalCitation · doi-reference

Targeting alpha-synuclein with a microRNA-embedded silencing vector in the rat substantia nigra: positive and negative effects

10.1016/j.brainres.2014.01.010 · ExternalCitation · doi-reference

Post-translational modification of α-synuclein in Parkinson’s disease

10.1016/j.brainres.2015.06.002 · ExternalCitation · doi-reference

The assays of activities and function of TH, AADC, and GCH1 and their potential use in ex vivo gene therapy of PD

10.1016/j.brainresprot.2005.10.005 · ExternalCitation · doi-reference

Small-molecule LRRK2 inhibitors for PD therapy: current achievements and future perspectives

10.1016/j.ejmech.2023.115475 · ExternalCitation · doi-reference

Silencing of human α-synuclein in vitro and in rat brain using lentiviral-mediated RNAi

10.1016/j.expneurol.2005.12.024 · ExternalCitation · doi-reference

AAV2-mediated striatum delivery of human CDNF prevents the deterioration of midbrain dopamine neurons in a 6-hydroxydopamine induced parkinsonian rat model

10.1016/j.expneurol.2013.06.002 · ExternalCitation · doi-reference

Progressive parkinsonism due to mitochondrial impairment: lessons from the MitoPark mouse model

10.1016/j.expneurol.2021.113707 · ExternalCitation · doi-reference

Characterization of nonmotor behavioral impairments and their neurochemical mechanisms in the MitoPark mouse model of progressive neurodegeneration in Parkinson’s disease

10.1016/j.expneurol.2021.113716 · ExternalCitation · doi-reference

Gene-modified animal models of Parkinson’s disease

10.1016/j.expneurol.2025.115287 · ExternalCitation · doi-reference

GDNF-Ret signaling in midbrain dopaminergic neurons and its implication for Parkinson disease

10.1016/j.febslet.2015.11.006 · ExternalCitation · doi-reference

Neuroprotective role of CHCHD2 in Parkinson’s disease: insights into the GPX4-related ferroptosis pathway

10.1016/j.freeradbiomed.2024.11.034 · ExternalCitation · doi-reference

Autophagy in Parkinson’s disease

10.1016/j.jmb.2020.01.037 · ExternalCitation · doi-reference

Oxidative stress mediated neuronal damage in the corpus striatum of 6-hydroxydopamine lesioned Parkinson’s rats: neuroprotection by Serotonin, GABA and Bone Marrow Cells Supplementation

10.1016/j.jns.2013.04.020 · ExternalCitation · doi-reference

Delayed gene therapy of glial cell line-derived neurotrophic factor is efficacious in a rat model of Parkinson’s disease

10.1016/j.molbrainres.2004.06.029 · ExternalCitation · doi-reference

Redox cycling of the herbicide paraquat in microglial cultures

10.1016/j.molbrainres.2004.11.005 · ExternalCitation · doi-reference

A highly reproducible rotenone model of Parkinson’s disease

10.1016/j.nbd.2009.01.016 · ExternalCitation · doi-reference

Glial-derived neurotrophic factor gene transfer for Parkinson’s disease: anterograde distribution of AAV2 vectors in the primate brain

10.1016/j.nbd.2011.10.004 · ExternalCitation · doi-reference

Progressive neurodegenerative and behavioural changes induced by AAV-mediated overexpression of α-synuclein in midbrain dopamine neurons

10.1016/j.nbd.2011.12.013 · ExternalCitation · doi-reference

Pharmacologically controlled, discontinuous GDNF gene therapy restores motor function in a rat model of Parkinson’s disease

10.1016/j.nbd.2014.01.009 · ExternalCitation · doi-reference

Post-mortem assessment of the short and long-term effects of the trophic factor neurturin in patients with α-synucleinopathies

10.1016/j.nbd.2015.03.023 · ExternalCitation · doi-reference

Glucocerebrosidase gene therapy prevents α-synucleinopathy of midbrain dopamine neurons

10.1016/j.nbd.2015.09.009 · ExternalCitation · doi-reference

Long-term RNAi knockdown of α-synuclein in the adult rat substantia nigra without neurodegeneration

10.1016/j.nbd.2019.01.004 · ExternalCitation · doi-reference

Loss of Parkin contributes to mitochondrial turnover and dopaminergic neuronal loss in aged mice

10.1016/j.nbd.2019.104717 · ExternalCitation · doi-reference

Synuclein activates microglia in a model of Parkinson’s disease

10.1016/j.neurobiolaging.2007.04.006 · ExternalCitation · doi-reference

Animal models of Parkinson’s disease: AN updated overview

10.1016/j.neurol.2015.07.011 · ExternalCitation · doi-reference

Genetic animal models of Parkinson’s Disease

10.1016/j.neuron.2010.04.034 · ExternalCitation · doi-reference

Synaptic vesicle recycling pathway determines neurotransmitter content and release properties

10.1016/j.neuron.2019.03.031 · ExternalCitation · doi-reference

Molecular and functional architecture of striatal dopamine release sites

10.1016/j.neuron.2021.10.028 · ExternalCitation · doi-reference

Down-regulation of DJ-1 Augments Neuroinflammation via Nrf2/Trx1/NLRP3 Axis in MPTP-induced Parkinson’s Disease Mouse Model

10.1016/j.neuroscience.2020.06.001 · ExternalCitation · doi-reference

Gene Therapy for Parkinson’s Disease: preclinical Evaluation of Optimally Configured TH:CH1 Fusion for Maximal Dopamine Synthesis

10.1016/j.omtm.2019.07.002 · ExternalCitation · doi-reference

Optimal different adeno-associated virus capsid/promoter combinations to target specific cell types in the common marmoset cerebral cortex

10.1016/j.omtm.2024.101337 · ExternalCitation · doi-reference

Splice-switching antisense oligonucleotides reduce LRRK2 kinase activity in human LRRK2 transgenic mice

10.1016/j.omtn.2020.06.027 · ExternalCitation · doi-reference

Characterization and reproducibility of a macaque model of Parkinson’s disease alpha-synucleinopathy

10.1016/j.parkreldis.2017.11.012 · ExternalCitation · doi-reference

Targeting the GBA1 pathway to slow Parkinson disease: insights into clinical aspects, pathogenic mechanisms and new therapeutic avenues

10.1016/j.pharmthera.2023.108419 · ExternalCitation · doi-reference

AAV-aMTD-Parkin, a therapeutic gene delivery cargo, enhances motor and cognitive functions in Parkinson’s and Alzheimer’s diseases

10.1016/j.phrs.2024.107326 · ExternalCitation · doi-reference

The neuropsychiatry of Parkinson’s disease and related disorders

10.1016/j.psc.2004.07.001 · ExternalCitation · doi-reference

A new target for an old DUB: UCH-L1 regulates mitofusin-2 levels, altering mitochondrial morphology, function and calcium uptake

10.1016/j.redox.2020.101676 · ExternalCitation · doi-reference

Can GBA1-associated Parkinson disease be modeled in the mouse?

10.1016/j.tins.2019.05.010 · ExternalCitation · doi-reference

AAV-PHP.B-mediated global-scale expression in the mouse nervous system enables GBA1 gene therapy for wide protection from synucleinopathy

10.1016/j.ymthe.2017.08.004 · ExternalCitation · doi-reference

Downregulation of SNCA expression by targeted editing of DNA methylation: a potential strategy for precision therapy in PD

10.1016/j.ymthe.2018.08.019 · ExternalCitation · doi-reference

Long-term safety of MRI-guided administration of AAV2-GDNF and gadoteridol in the putamen of individuals with Parkinson’s disease

10.1016/j.ymthe.2022.08.003 · ExternalCitation · doi-reference

Recent developments in gene therapy for Parkinson’s disease

10.1016/j.ymthe.2025.03.030 · ExternalCitation · doi-reference

Alterations of structure and hydrolase activity of parkinsonism-associated human ubiquitin carboxyl-terminal hydrolase L1 variants

10.1016/s0006-291x(03)00555-2 · ExternalCitation · doi-reference

Adenoviral vector-mediated GDNF gene therapy in a rodent lesion model of late stage Parkinson’s disease

10.1016/s0006-8993(97)01100-1 · ExternalCitation · doi-reference

The MPTP-lesioned non-human primate models of Parkinson’s disease. Past, present, and future

10.1016/s0079-6123(10)84007-5 · ExternalCitation · doi-reference

Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson’s disease: an open label, phase I trial

10.1016/s0140-6736(07)60982-9 · ExternalCitation · doi-reference

Long-term safety and tolerability of ProSavin, a lentiviral vector-based gene therapy for Parkinson’s disease: a dose escalation, open-label, phase 1/2 trial

10.1016/s0140-6736(13)61939-x · ExternalCitation · doi-reference

Pimavanserin for patients with Parkinson’s disease psychosis: a randomised, placebo-controlled phase 3 trial

10.1016/s0140-6736(13)62106-6 · ExternalCitation · doi-reference

Parkinson’s disease

10.1016/s0140-6736(21)00218-x · ExternalCitation · doi-reference

Molecular pathways involved in the neurotoxicity of 6-OHDA, dopamine and MPTP: contribution to the apoptotic theory in Parkinson’s disease

10.1016/s0301-0082(01)00003-x · ExternalCitation · doi-reference

Intravenous amantadine sulphate application improves the performance of complex but not simple motor tasks in patients with Parkinson’s disease

10.1016/s0304-3940(02)01462-3 · ExternalCitation · doi-reference

What do clinical trials tell us about treating patients?

10.1016/s1353-8020(09)70776-x · ExternalCitation · doi-reference

Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2-neurturin) to patients with idiopathic Parkinson’s disease: an open-label, phase I trial

10.1016/s1474-4422(08)70065-6 · ExternalCitation · doi-reference

Neuroinflammation in Parkinson’s disease: a target for neuroprotection?

10.1016/s1474-4422(09)70062-6 · ExternalCitation · doi-reference

Gene delivery of AAV2-neurturin for Parkinson’s disease: a double-blind, randomised, controlled trial

10.1016/s1474-4422(10)70254-4 · ExternalCitation · doi-reference

AAV2-GAD gene therapy for advanced Parkinson’s disease: a double-blind, sham-surgery controlled, randomised trial

10.1016/s1474-4422(11)70039-4 · ExternalCitation · doi-reference

Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson’s disease: a randomised, controlled, double-blind, double-dummy study

10.1016/s1474-4422(13)70293-x · ExternalCitation · doi-reference

Apomorphine subcutaneous infusion in patients with Parkinson’s disease with persistent motor fluctuations (Toledo): a multicentre, double-blind, randomised, placebo-controlled trial

10.1016/s1474-4422(18)30239-4 · ExternalCitation · doi-reference

The burden of Parkinson’s disease: a worldwide perspective

10.1016/s1474-4422(18)30355-7 · ExternalCitation · doi-reference

Gene therapy for Parkinson’s disease: trials and technical advances

10.1016/s1474-4422(25)00125-5 · ExternalCitation · doi-reference

Pre-fibrillar α-synuclein variants with impaired Β-structure increase neurotoxicity in Parkinson’s disease models

10.1038/emboj.2009.257 · ExternalCitation · doi-reference

Axonal transport of adeno-associated viral vectors is serotype-dependent

10.1038/gt.2012.27 · ExternalCitation · doi-reference

A phase i study of aromatic l-amino acid decarboxylase gene therapy for Parkinson’s disease

10.1038/mt.2010.135 · ExternalCitation · doi-reference

Enhanced efficacy of the CDNF/MANF family by Combined intranigral overexpression in the 6-OHDA Rat Model of Parkinson’s disease

10.1038/mt.2014.206 · ExternalCitation · doi-reference

Mitochondrial dysfunction in Drosophila PINK1 mutants is complemented by parkin

10.1038/nature04788 · ExternalCitation · doi-reference

α-Synuclein occurs physiologically as a helically folded tetramer that resists aggregation

10.1038/nature10324 · ExternalCitation · doi-reference

Loss of Parkinson’s disease-associated protein CHCHD2 affects mitochondrial crista structure and destabilizes cytochrome c

10.1038/ncomms15500 · ExternalCitation · doi-reference

Protocol for the MPTP mouse model of Parkinson’s disease

10.1038/nprot.2006.342 · ExternalCitation · doi-reference

Initiation of Parkinson’s disease from gut to brain by δ-secretase

10.1038/s41422-019-0241-9 · ExternalCitation · doi-reference

To restrict or not to restrict? Practical considerations for optimizing dietary protein interactions on levodopa absorption in Parkinson’s disease

10.1038/s41531-023-00541-w · ExternalCitation · doi-reference

Adult-onset deletion of ATP13A2 in mice induces progressive nigrostriatal pathway dopaminergic degeneration and lysosomal abnormalities

10.1038/s41531-024-00748-5 · ExternalCitation · doi-reference

Nigral ATP13A2 depletion induces Parkinson’s disease-related neurodegeneration in a pilot study in non-human primates

10.1038/s41531-024-00757-4 · ExternalCitation · doi-reference

The role of PINK1–Parkin in mitochondrial quality control

10.1038/s41556-024-01513-9 · ExternalCitation · doi-reference

ATP13A2 deficiency disrupts lysosomal polyamine export

10.1038/s41586-020-1968-7 · ExternalCitation · doi-reference

Gut-seeded α-synuclein fibrils promote gut dysfunction and brain pathology specifically in aged mice

10.1038/s41593-020-0589-7 · ExternalCitation · doi-reference

Activation of the mitochondrial unfolded protein response promotes longevity and dopamine neuron survival in Parkinson’s disease models

10.1038/s41598-017-16637-2 · ExternalCitation · doi-reference

Drosophila Ubiquitin C-Terminal Hydrolase Knockdown Model of Parkinson’s Disease

10.1038/s41598-018-22804-w · ExternalCitation · doi-reference

Delivery of CDNF by AAV-mediated gene transfer protects dopamine neurons and regulates ER stress and inflammation in an acute MPTP mouse model of Parkinson’s disease

10.1038/s41598-024-65735-5 · ExternalCitation · doi-reference

Enhanced expression of glutamate decarboxylase 65 improves symptoms of rat parkinsonian models

10.1038/sj.gt.3302520 · ExternalCitation · doi-reference

Subthalamic glutamic acid decarboxylase gene therapy: changes in motor function and cortical metabolism

10.1038/sj.jcbfm.9600364 · ExternalCitation · doi-reference

The parkinsonian toxin 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine (MPTP): a technical review of its utility and safety

10.1046/j.1471-4159.2001.00183.x · ExternalCitation · doi-reference

Rivastigmine for dementia associated with Parkinson’s disease

10.1056/nejmoa041470 · ExternalCitation · doi-reference

Randomized trial of focused ultrasound subthalamotomy for Parkinson’s disease

10.1056/nejmoa2016311 · ExternalCitation · doi-reference

Trial of globus pallidus focused ultrasound ablation in Parkinson’s disease

10.1056/nejmoa2202721 · ExternalCitation · doi-reference

Nigrostriatal α-synucleinopathy induced by viral vector-mediated overexpression of human α-synuclein: a new primate model of Parkinson’s disease

10.1073/pnas.0536383100 · ExternalCitation · doi-reference

Progressive parkinsonism in mice with respiratory-chain-deficient dopamine neurons

10.1073/pnas.0605208103 · ExternalCitation · doi-reference

CNS expression of glucocerebrosidase corrects α-synuclein pathology and memory in a mouse model of Gaucher-related synucleinopathy

10.1073/pnas.1108197108 · ExternalCitation · doi-reference

sAugmenting CNS glucocerebrosidase activity as a therapeutic strategy for parkinsonism and other Gaucher-related synucleinopathies

10.1073/pnas.1220464110 · ExternalCitation · doi-reference

Robust kinase- and age-dependent dopaminergic and norepinephrine neurodegeneration in LRRK2 G2019S transgenic mice

10.1073/pnas.1712648115 · ExternalCitation · doi-reference

TrkB neurotrophic activities are blocked by α-synuclein, triggering dopaminergic cell death in Parkinson’s disease

10.1073/pnas.1713969114 · ExternalCitation · doi-reference

Convection-enhanced delivery of macromolecules in the brain

10.1073/pnas.91.6.2076 · ExternalCitation · doi-reference

Soluble, prefibrillar α-synuclein oligomers promote complex I-dependent, Ca2+-induced mitochondrial dysfunction

10.1074/jbc.m113.545749 · ExternalCitation · doi-reference

Wild-type PINK1 prevents basal and induced neuronal apoptosis, a protective effect abrogated by Parkinson disease-related mutations

10.1074/jbc.m505143200 · ExternalCitation · doi-reference

Fibrillar α-synuclein toxicity depends on functional lysosomes

10.1074/jbc.ra120.013428 · ExternalCitation · doi-reference

Mitochondrial dysfunction and mitophagy defect triggered by heterozygous GBA mutations

10.1080/15548627.2018.1509818 · ExternalCitation · doi-reference

Localization of a novel locus for autosomal recessive early-onset parkinsonism, PARK6, on human chromosome 1p35-p36

10.1086/319522 · ExternalCitation · doi-reference

10.1089/hum.2004.15.1177

10.1089/hum.2004.15.1177 · ExternalCitation · doi-reference

Long-term safety of patients with Parkinson’s disease receiving rAAV2-neurturin (CERE-120) gene transfer

10.1089/hum.2015.134 · ExternalCitation · doi-reference

Long-term follow-up of a phase I/II study of ProSavin, a lentiviral vector gene therapy for Parkinson’s disease

10.1089/humc.2018.081 · ExternalCitation · doi-reference

Parkinson’s disease and residential exposure to Maneb and Paraquat from agricultural applications in the Central Valley of California

10.1093/aje/kwp006 · ExternalCitation · doi-reference

Disease duration and the integrity of the nigrostriatal system in Parkinson’s disease

10.1093/brain/awt192 · ExternalCitation · doi-reference

The L444P Gba1 mutation enhances alpha-synuclein induced loss of nigral dopaminergic neurons in mice

10.1093/brain/awx221 · ExternalCitation · doi-reference

Mutant LRRK2 mediates peripheral and central immune responses leading to neurodegeneration in vivo

10.1093/brain/awy077 · ExternalCitation · doi-reference

Randomized trial of intermittent intraputamenal glial cell line-derived neurotrophic factor in Parkinson’s disease

10.1093/brain/awz023 · ExternalCitation · doi-reference

Viral alpha-synuclein knockdown prevents spreading synucleinopathy

10.1093/braincomms/fcab247 · ExternalCitation · doi-reference

Homeostatic p62 levels and inclusion body formation in CHCHD2 knockout mice

10.1093/hmg/ddab057 · ExternalCitation · doi-reference

Autophagic lysosome reformation dysfunction in glucocerebrosidase deficient cells: relevance to Parkinson disease

10.1093/hmg/ddw185 · ExternalCitation · doi-reference

Trophic factors for Parkinson’s disease: where are we and where do we go from here?

10.1111/ejn.14102 · ExternalCitation · doi-reference

Seeding induced by alpha-synuclein oligomers provides evidence for spreading of alpha-synuclein pathology

10.1111/j.1471-4159.2009.06324.x · ExternalCitation · doi-reference

VMAT2: a dynamic regulator of brain monoaminergic neuronal function interacting with drugs of abuse

10.1111/j.1749-6632.2010.05906.x · ExternalCitation · doi-reference

Enhancing aromatic L-amino acid decarboxylase activity: implications for L-DOPA treatment in Parkinson’s disease

10.1111/j.1755-5949.2008.00058.x · ExternalCitation · doi-reference

How can rAAV ‐α‐synuclein and the fibril α‐synuclein models advance our understanding of Parkinson’s disease?

10.1111/jnc.13627 · ExternalCitation · doi-reference

The clinical symptoms of Parkinson’s disease

10.1111/jnc.13691 · ExternalCitation · doi-reference

Subthalamic GAD gene therapy in a Parkinson’s disease rat model

10.1126/science.1074549 · ExternalCitation · doi-reference

Pathological α-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice

10.1126/science.1227157 · ExternalCitation · doi-reference

Preclinical and clinical evaluation of the LRRK2 inhibitor DNL201 for Parkinson’s disease

10.1126/scitranslmed.abj2658 · ExternalCitation · doi-reference

Projections for prevalence of Parkinson’s disease and its driving factors in 195 countries and territories to 2050: modelling study of Global Burden of Disease Study 2021

10.1136/bmj-2024-080952 · ExternalCitation · doi-reference

Deep brain stimulation for Parkinson’s disease: systematic review with meta-analysis and trial sequential analysis

10.1136/bmjmed-2023-000705 · ExternalCitation · doi-reference

Data-driven evolution of neurosurgical gene therapy delivery in Parkinson’s disease

10.1136/jnnp-2020-322904 · ExternalCitation · doi-reference

L-DOPA uptake in astrocytic endfeet enwrapping blood vessels in rat brain

10.1155/2012/321406 · ExternalCitation · doi-reference

Adeno-associated virus Type 2 vector-mediated glial cell line-derived neurotrophic factor gene transfer induces neuroprotection and neuroregeneration in a ubiquitin-proteasome system impairment animal model of Parkinson’s disease

10.1159/000334527 · ExternalCitation · doi-reference

ShRNA targeting α-synuclein prevents neurodegeneration in a Parkinson’s disease model

10.1172/jci64502 · ExternalCitation · doi-reference

10.1186/1750-1326-5-43

10.1186/1750-1326-5-43 · ExternalCitation · doi-reference

rAAV2/7 vector-mediated overexpression of alpha-synuclein in mouse substantia nigra induces protein aggregation and progressive dose-dependent neurodegeneration

10.1186/1750-1326-8-44 · ExternalCitation · doi-reference

A CRISPR monkey model unravels a unique function of PINK1 in primate brains

10.1186/s13024-019-0321-9 · ExternalCitation · doi-reference

PINK1 and Parkin mitochondrial quality control: a source of regional vulnerability in Parkinson’s disease

10.1186/s13024-020-00367-7 · ExternalCitation · doi-reference

Oxidative stress and cellular pathologies in Parkinson’s disease

10.1186/s13041-017-0340-9 · ExternalCitation · doi-reference

Role of GABA pathway in motor and non-motor symptoms in Parkinson’s disease: a bidirectional circuit

10.1186/s40001-024-01779-7 · ExternalCitation · doi-reference

AAV1/2-induced overexpression of A53T-α-synuclein in the substantia nigra results in degeneration of the nigrostriatal system with Lewy-like pathology and motor impairment: a new mouse model for Parkinson’s disease

10.1186/s40478-017-0416-x · ExternalCitation · doi-reference

Pathogenic alpha-synuclein aggregates preferentially bind to mitochondria and affect cellular respiration

10.1186/s40478-019-0696-4 · ExternalCitation · doi-reference

Early-onset impairment of the ubiquitin-proteasome system in dopaminergic neurons caused by α-synuclein

10.1186/s40478-020-0894-0 · ExternalCitation · doi-reference

Results from a phase I safety trial of hAADC gene therapy for Parkinson disease

10.1212/01.wnl.0000312381.29287.ff · ExternalCitation · doi-reference

Advances in levodopa therapy for Parkinson disease

10.1212/wnl.0000000000002510 · ExternalCitation · doi-reference

Safety of AADC gene therapy for moderately advanced Parkinson disease: three-year outcomes from the PD-1101 trial

10.1212/wnl.0000000000012952 · ExternalCitation · doi-reference

Safety and tolerability of putaminal AADC gene therapy for Parkinson disease

10.1212/wnl.0b013e3181c29356 · ExternalCitation · doi-reference

A randomized, double-blind, placebo-controlled trial of antidepressants in Parkinson disease

10.1212/wnl.0b013e3182516244 · ExternalCitation · doi-reference

Randomized trial of deep brain stimulation for Parkinson disease: thirty-six-month outcomes

10.1212/wnl.0b013e31825dcdc1 · ExternalCitation · doi-reference

Safety/feasibility of targeting the substantia nigra with AAV2-neurturin in Parkinson patients

10.1212/wnl.0b013e3182904faa · ExternalCitation · doi-reference

Rotenone, paraquat, and Parkinson’s disease

10.1289/ehp.1002839 · ExternalCitation · doi-reference

Lrrk promotes tau neurotoxicity through dysregulation of actin and mitochondrial dynamics

10.1371/journal.pbio.2006265 · ExternalCitation · doi-reference

Therapeutic efficacy of AAV8-mediated intrastriatal delivery of human cerebral dopamine neurotrophic factor in 6-OHDA-induced parkinsonian rat models with different disease progression

10.1371/journal.pone.0179476 · ExternalCitation · doi-reference

Modeling α-synuclein propagation with preformed Fibril injections

10.14802/jmd.19046 · ExternalCitation · doi-reference

Mutant alpha-synuclein causes age-dependent neuropathology in monkey brain

10.1523/jneurosci.0772-15.2015 · ExternalCitation · doi-reference

Regeneration of the MPTP-lesioned dopaminergic system after convection-enhanced delivery of AAV2-GDNF

10.1523/jneurosci.0942-10.2010 · ExternalCitation · doi-reference

Parkinson’s disease-associated LRRK2 hyperactive kinase mutant disrupts synaptic vesicle trafficking in ventral midbrain neurons

10.1523/jneurosci.0964-17.2017 · ExternalCitation · doi-reference

Parkinson-like neurodegeneration induced by targeted overexpression of α-synuclein in the nigrostriatal system

10.1523/jneurosci.22-07-02780.2002 · ExternalCitation · doi-reference

Dynamic changes in presynaptic and axonal transport proteins combined with striatal neuroinflammation precede dopaminergic neuronal loss in a rat model of AAV α-synucleinopathy

10.1523/jneurosci.5427-08.2009 · ExternalCitation · doi-reference

Gene therapy in the putamen for curing AADC deficiency and Parkinson’s disease

10.15252/emmm.202114712 · ExternalCitation · doi-reference

A review on Parkinson’s disease treatment

10.20517/2347-8659.2020.58 · ExternalCitation · doi-reference

Levodopa/carbidopa and entacapone in the treatment of Parkinson’s disease: efficacy, safety and patient preference

10.2147/ppa.s4084 · ExternalCitation · doi-reference

Tetrahydrobioterin (BH4) pathway: from metabolism to neuropsychiatry

10.2174/1570159x18666200729103529 · ExternalCitation · doi-reference

Advances in the therapeutic use of non-ergot dopamine agonists in the treatment of motor and non-motor symptoms of Parkinson’s disease

10.2174/1570159x20666220915091022 · ExternalCitation · doi-reference

Gene therapy for Parkinson’s disease, an update

10.3233/jpd-181331 · ExternalCitation · doi-reference

MPTP mouse models of Parkinson’s disease: an update

10.3233/jpd-2011-11023 · ExternalCitation · doi-reference

Next-Generation Gene Therapy for Parkinson’s Disease Using Engineered Viral Vectors

10.3233/jpd-212674 · ExternalCitation · doi-reference

An update on gene therapy approaches for Parkinson’s disease: restoration of dopaminergic function

10.3233/jpd-212724 · ExternalCitation · doi-reference

DJ-1 inhibits α-synuclein aggregation by regulating chaperone-mediated autophagy

10.3389/fnagi.2017.00308 · ExternalCitation · doi-reference

Alpha-synuclein spreading in Parkinson’s disease

10.3389/fnana.2014.00159 · ExternalCitation · doi-reference

Alterations in neuronal activity in basal ganglia-thalamocortical circuits in the Parkinsonian State

10.3389/fnana.2015.00005 · ExternalCitation · doi-reference

Presynaptic Mechanisms of l-DOPA-Induced Dyskinesia: the Findings, the Debate, and the Therapeutic Implications

10.3389/fneur.2014.00242 · ExternalCitation · doi-reference

Silencing of glucocerebrosidase gene in drosophila enhances the aggregation of Parkinson’s disease associated α-synuclein mutant A53T and affects locomotor activity

10.3389/fnins.2018.00081 · ExternalCitation · doi-reference

Glitazone treatment rescues phenotypic deficits in a fly model of Gaucher/Parkinson’s Disease

10.3390/ijms222312740 · ExternalCitation · doi-reference

Management of REM sleep behavior disorder: an American Academy of Sleep Medicine clinical practice guideline

10.5664/jcsm.10424 · ExternalCitation · doi-reference

Initial elevations in glutamate and dopamine neurotransmission decline with age, as does exploratory behavior, in LRRK2 G2019S knock-in mice

10.7554/elife.28377 · ExternalCitation · doi-reference